KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Common Equity: 2018-2024

Historic Common Equity for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to -$388.7 million.

  • Esperion Therapeutics' Common Equity fell 21.92% to -$451.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$451.4 million, marking a year-over-year decrease of 21.92%. This contributed to the annual value of -$388.7 million for FY2024, which is 14.57% up from last year.
  • As of FY2024, Esperion Therapeutics' Common Equity stood at -$388.7 million, which was up 14.57% from -$455.0 million recorded in FY2023.
  • Over the past 5 years, Esperion Therapeutics' Common Equity peaked at -$96.1 million during FY2020, and registered a low of -$455.0 million during FY2023.
  • Moreover, its 3-year median value for Common Equity was -$388.7 million (2024), whereas its average is -$389.2 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Common Equity crashed by 581.87% in 2020, and later climbed by 14.57% in 2024.
  • Esperion Therapeutics' Common Equity (Yearly) stood at -$96.1 million in 2020, then slumped by 104.86% to -$196.9 million in 2021, then crashed by 64.40% to -$323.8 million in 2022, then tumbled by 40.53% to -$455.0 million in 2023, then climbed by 14.57% to -$388.7 million in 2024.